Vera Therapeutics, Inc. (VERA)
VERANASDAQ-GMBiotechnology: Pharmaceutical Preparations
$28.96
-0.0800 (-0.28%) today
Regular session, Nov 13, 9:30 AM ET
- Market cap
- $2.06bn
- P/E
- –
- EPS, last 4 quarters
- $-5.90
- Dividend yield
- –
- Day range
- $28.45 to $28.96
- 52-week range
- $26.38 to $56.05
- Average volume
- –
- Previous close
- $29.04
Analysts
12 coveringBuy10 buy, 2 hold, 0 sell
Targets a year out average $68.73, +137.3% from here
Earnings
next estimate $-1.46Next report
Dec 2025
-3.7%
Mar 2026
-34.1%
Jun 2026
+5.0%
Sep 2026
+24.4%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | $10.28m |
| Gross profit | – | – | – | $6.98m |
| Operating income | -$94.21m | -$125.13m | -$112.49m | -$95.70m |
| Net income | -$91.10m | -$121.03m | -$109.47m | -$93.71m |
News
8 latest- Vera Therapeutics Q3 Earnings Call HighlightsMarketBeat · 7 days ago
- Vera Therapeutics Reports Third Quarter 2026 Financial ResultsFintel · Nov 6, 2026
- Vera Therapeutics (VERA) Q3 2026 Earnings Call TranscriptThe Motley Fool · Nov 6, 2026
- Vera Therapeutics, Inc. (VERA) Reports Q3 Loss, Tops Revenue EstimatesZacks · Nov 5, 2026
- Weekly Buzz: AZN, ALVO Score FDA Nod; EYPT Cuts Jobs; RHHBY, GEHC Enter Deal; VERA Posts Trial Win RTTNews · Oct 23, 2026
- Vera Therapeutics' TRUTAKNA Delivers Strong Phase III IgA Nephropathy ResultsMarketBeat · Oct 22, 2026
- Vera's TRUTAKNA Shows Kidney Benefit In Final Phase 3 IgA Nephropathy Analysis RTTNews · Oct 22, 2026
- Leerink Partners Initiates Coverage of Vera Therapeutics at Market PerformFintel · Oct 12, 2026
The company
Vera Therapeutics is a commercial-stage biotechnology company focused on the pursuit of truth in science to transform medicine in autoimmune disease, starting with the kidney. Vera Therapeutics' flagship commercial product is TRUTAKNA (atacicept-vymj), a B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL) inhibitor. Vera Therapeutics is evaluating multiple diseases where the reduction of autoantibodies through inhibition of BAFF and APRIL may prove clinically meaningful. Vera Therapeutics was founded in 2016 and is based in Brisbane, California.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-GM
- Region
- North America
- Website
- veratx.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.